List prices in pharmaceuticals are less prices than they are political objects—numbers that exist to be negotiated away, invoiced and rebated, cited in earnings calls, and disputed in congressional hearings, while rarely corresponding to any actual transaction in the supply chain. The wholesale acquisition cost, or WAC, occupies a peculiar position in this theater: it is simultaneously the most cited and least paid price in the American drug market. MedPricer.org, a drug pricing data platform aggregating WAC, ASP, and NADAC across time, treats this gap not as a curiosity but as an analytical signal.
The Architecture of a Fictional Price
WAC was never designed to represent what manufacturers receive. It was designed as a benchmark—a common reference point from which contracts, rebates, and reimbursements could be calculated. That design choice, reasonable in a simpler market, has become increasingly difficult to interpret as gross-to-net adjustments have grown in scale. Some branded therapies now carry gross-to-net gaps exceeding sixty percent. The list price, in such cases, is less a market signal than a negotiating anchor—a number that exists primarily to be discounted.
The problem for investors, analysts, and policymakers is that WAC is still the number reported, cited, and legislatively referenced. IQVIA data and CMS quarterly ASP files exist in separate repositories, updated on different schedules, using different drug identifiers. No single platform has historically made it easy to trend these benchmarks against one another. That gap—informational, not just transactional—is precisely what MedPricer addresses.
When the Spread Starts to Move
Consider what happens when WAC rises five percent in a quarter while ASP moves less than one. The naive interpretation is that manufacturers are raising prices. The more accurate interpretation, often, is that they are raising list prices while simultaneously expanding rebate arrangements to maintain formulary position. The effective price—the one that actually flows through the gross-to-net calculation—may be flat or declining even as the headline number climbs.
This matters asymmetrically across stakeholders. For a pharmacy benefit manager negotiating against WAC, the spread is leverage. For a Medicare Part B program reimbursing at ASP plus six percent, a widening spread means the government is paying on an increasingly artificial benchmark. For a manufacturer investor, a WAC increase accompanied by flat ASP is not revenue expansion—it is rebate inflation dressed as pricing power.
MedPricer’s value proposition is precisely this interpretive layer. The datasets are public. CMS publishes ASP quarterly. NADAC comes from the Pharmacy Pricing Survey. WAC is available through multiple commercial aggregators. The analytical work—normalizing across NDC identifiers, aligning quarterly update cycles, computing trailing spreads—is where the platform earns its claim to investor attention.
The Second-Order Problem: What Flat ASP Conceals
A stable ASP is not necessarily a stable market. When WAC rises and ASP holds, the stability in ASP can reflect one of several dynamics: rebates absorbing the increase, formulary exclusions limiting utilization at the higher WAC, or payer resistance successfully constraining effective price. Each of these mechanisms has different implications for manufacturer gross margins, channel profitability, and competitive positioning.
MedPricer’s cross-dataset approach surfaces the divergence without pre-assigning causality—which is, arguably, the appropriate epistemic posture given how opaque the rebate ecosystem remains. The platform can show that WAC rose 7% while ASP rose 1.2% over six quarters for a given drug class. It cannot tell you whether that gap reflects a single large rebate arrangement, a portfolio deal, or index-linked formulary contracts. The interpretive work remains with the analyst. But the signal, stripped of interpretive assumption, is now visible.
Why WAC Transparency May Accelerate Without Simplifying the Market
Legislative attention to list price transparency—state-level price reporting requirements, the Inflation Reduction Act’s negotiation framework, CMS’s expanded transparency rules—has created more WAC disclosure without necessarily more WAC clarity. A manufacturer can disclose a WAC that no one pays and remain technically compliant with reporting requirements while the underlying economics remain opaque.
The irony is that greater WAC visibility may actually increase the strategic value of ASP and NADAC data. If list prices are now disclosed but rebate structures remain confidential, the spread between WAC and ASP becomes the primary inference tool available to outside analysts. MedPricer’s architecture—built on exactly that inference—is positioned at the intersection of a transparency policy environment and a persistently opaque rebate ecosystem. That combination is not a market inefficiency to be resolved. It may be a structural feature of how U.S. drug pricing is designed to work.
